OOIR: Observatory of International Research

Papers

(The TQCC of Movement Disorders is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy	228
Meta‐Analysis of Gut Dysbiosis in Parkinson's Disease	199
Outcome of Parkinson's Disease Patients Affected by COVID‐19	178
Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease	177
Effects of COVID‐19 on Parkinson's Disease Clinical Features: A Community‐Based Case‐Control Study	142
Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease	129
COVID‐19 in Parkinson’s Disease Patients Living in Lombardy, Italy	122
Mental Health, Physical Activity, and Quality of Life in Parkinson's Disease During COVID‐19 Pandemic	122
Impact of the COVID‐19 Pandemic on Parkinson's Disease and Movement Disorders	110
SARS‐CoV‐2: At the Crossroad Between Aging and Neurodegeneration	107
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression	102
Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression	102
Genome‐Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease	101
Coronavirus Disease 2019 and Parkinsonism: A Non‐post‐encephalitic Case	90
Parkinson's Disease and COVID‐19: Perceptions and Implications in Patients and Caregivers	89
Blinded RT‐QuIC Analysis of α‐Synuclein Biomarker in Skin Tissue From Parkinson's Disease Patients	86
Rapid Onset Functional Tic‐Like Behaviors in Young Females During the COVID‐19 Pandemic	86
Guidelines for Speech Recording and Acoustic Analyses in Dysarthrias of Movement Disorders	84
Incidence of Anxiety in Parkinson's Disease During the Coronavirus Disease (COVID‐19) Pandemic	83
GBA‐Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort	80
GP2: The Global Parkinson's Genetics Program	77
Genotype–Phenotype Relations for Isolated Dystonia Genes: MDSGene Systematic Review	74
Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review	73
Global Survey on Telemedicine Utilization for Movement Disorders During the COVID‐19 Pandemic	72
Integrated Care in Parkinson's Disease: A Systematic Review and Meta‐Analysis	70

Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation	70
The Parkinson's Disease Genome‐Wide Association Study Locus Browser	67
Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease	64
Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease	63
Synaptic Loss in Primary Tauopathies Revealed by [¹¹C]UCB‐J Positron Emission Tomography	61
Validation of α‐Synuclein in L1CAM‐Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes	61
The Role of Cholesterol in α‐Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease	59
Nonsteroidal Anti‐inflammatory Use and LRRK2 Parkinson's Disease Penetrance	58
Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource	57
RT‐QuIC Detection of Pathological α‐Synuclein in Skin Punches of Patients with Lewy Body Disease	56
Bilateral Focused Ultrasound Thalamotomy for Essential Tremor (BEST‐FUS Phase 2 Trial)	54
GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes	54
Coronavirus Disease 2019 Case Fatality and Parkinson's Disease	53
International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease	53
Pandemic Tic‐like Behaviors Following Social Media Consumption	53
A Novel SNCA A30G Mutation Causes Familial Parkinsonʼs Disease	53
A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy	53
Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations	52
Closed‐Loop Deep Brain Stimulation for Essential Tremor Based on Thalamic Local Field Potentials	52
Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders	52
Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease	52
Differences in the Presentation and Progression of Parkinson's Disease by Sex	52
Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum	51
Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker	51
The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings	50
Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease	50
Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force – An Update	50
MIND and Mediterranean Diets Associated with Later Onset of Parkinson's Disease	49
Electroconvulsive Therapy for Parkinson's Disease: A Systematic Review and Meta‐Analysis	48
Impact of Coronavirus Disease 2019 Pandemic on Parkinson's Disease: A Cross‐Sectional Survey of 568 Spanish Patients	48
Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease	48
Skin Biopsy May Help to Distinguish Multiple System Atrophy–Parkinsonism from Parkinson's Disease With Orthostatic Hypotension	48
Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities	48
Penetrance of Glucocerebrosidase (GBA) Mutations in Parkinson's Disease: A Kin Cohort Study	48
α‐Synuclein in Plasma‐Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease	47
European Academy of Neurology/Movement Disorder Society‐European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies	47
Cortical [¹⁸F]PI‐2620 Binding Differentiates Corticobasal Syndrome Subtypes	46
GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10‐Year Population‐Based Study	46
Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug‐Naive Parkinson's Disease	45
Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial	45
Risk of Hospitalization and Death for COVID‐19 in People with Parkinson's Disease or Parkinsonism	44
Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms	44
Clinical Utility of ¹⁸F‐APN‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy	42
Prevalence of Parkinson's Disease: A Community‐Based Study in China	41
A Large‐Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands	41
Diabetes Causes Dysfunctional Dopamine Neurotransmission Favoring Nigrostriatal Degeneration in Mice	41
A Critical Review of White Matter Changes in Huntington’s Disease	41
Development and Validation of a Patient‐Reported Outcome Measure of Ataxia	40
Prodromal Spinocerebellar Ataxia Type 2 Subjects Have Quantifiable Gait and Postural Sway Deficits	40
Dopamine Receptors in Parkinson's Disease: A Meta‐Analysis of Imaging Studies	40

Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study	40
Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease	40
Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning	39
Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta‐Analysis	39
Reduced Synaptic Density in Patients with Lewy Body Dementia: An [¹¹C]UCB‐J PET Imaging Study	39
A Comprehensive Review of Brain Connectomics and Imaging to Improve Deep Brain Stimulation Outcomes	39
The Mutation Matters: CSF Profiles of GCase, Sphingolipids, α‐Synuclein in PD_GBA	39
Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease	38
The Possible Protective Role of α‐Synuclein Against Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Patients With Parkinson's Disease	38
Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease	38
Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs	37
Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2‐Hydroxypropyl‐β‐Cyclodextrin Treatment	37
Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder	37
Peripheral Immune Profile and Neutrophil‐to‐Lymphocyte Ratio in Parkinson's Disease	37
In Vivo Assessment of Neuroinflammation in 4‐Repeat Tauopathies	36
Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson's Disease	36
Cognitive Determinants of Dysarthria in Parkinson's Disease: An Automated Machine Learning Approach	36
A Randomized, Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait	36
Regional Brain and Spinal Cord Volume Loss in Spinocerebellar Ataxia Type 3	36
Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease	36
A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders	36
Development of SARA^home, a New Video‐Based Tool for the Assessment of Ataxia at Home	36
The Impact of COVID‐19 on Access to Parkinson's Disease Medication	36
Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease	35
Genotype–Phenotype Relations in Primary Familial Brain Calcification: Systematic MDSGene Review	34
Clinical Profiles and Mortality of COVID‐19 Inpatients with Parkinson's Disease in Germany	34
Movement Disorder Society–Unified Parkinson's Disease Rating Scale Use in the Covid‐19 Era	34
CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories	34
Abstracts	33
Action Observation and Motor Imagery Improve Dual Task in Parkinson's Disease: A Clinical/fMRI Study	33
α‐Synuclein Spread from Olfactory Bulb Causes Hyposmia, Anxiety, and Memory Loss in BAC‐SNCA Mice	33
Diagnostic Value of Salivary Real‐Time Quaking‐Induced Conversion in Parkinson's Disease and Multiple System Atrophy	33
Voice Analysis with Machine Learning: One Step Closer to an Objective Diagnosis of Essential Tremor	33
Expiratory Muscle Strength Training for Therapy of Pharyngeal Dysphagia in Parkinson's Disease	33
Stress and Mindfulness in Parkinson's Disease: Clinical Effects and Potential Underlying Mechanisms	33
Unmet Needs of Women Living with Parkinson's Disease: Gaps and Controversies	33
Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease	33
The Neurophysiology of Sleep in Parkinson's Disease	33
Gait Variability in Spinocerebellar Ataxia Assessed Using Wearable Inertial Sensors	33
Dissecting the Phenotype and Genotype of PLA2G6‐Related Parkinsonism	32
Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed‐Start Analysis of the MOXIe Extension	32
Seven Solutions for Neuroprotection in Parkinson's Disease	32
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers	32
Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease	32
Brain Structural Changes in Focal Dystonia—What About Task Specificity? A Multimodal MRI Study	32
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals	31
Covid‐19 Infection and Parkinsonism: Is There a Link?	31
Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?	31
The Impact of Type 2 Diabetes in Parkinson's Disease	31
Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures	31
Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset	30
Four‐Year Follow‐up of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography–Based Parkinson's Disease–Related Pattern Expression in 20 Patients with Isolated Rapid Eye Movement S	30
Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease	30
Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient‐Derived Neurons	30
Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early‐Onset Parkinson's Disease	30
The Gut Metabolite Trimethylamine N‐oxide Is Associated With Parkinson's Disease Severity and Progression	30
Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism	30
Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy	30
Recent Advances in the Development of Stem‐Cell‐Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease	30
Abstracts of the MDS Virtual Congress 2021	29
Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease	29
Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation	29
Impact of Coronavirus Disease 2019 Pandemic on Cognition in Parkinson's Disease	29
Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Randomization Approach	28
Magnetic Resonance Imaging Biomarkers Distinguish Normal Pressure Hydrocephalus From Progressive Supranuclear Palsy	28
Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting	28
Pedunculopontine Nucleus Microstructure Predicts Postural and Gait Symptoms in Parkinson's Disease	28
The Phenotypic and Genetic Spectrum of Paroxysmal Kinesigenic Dyskinesia in China	28
The Logic and Pitfalls of Parkinson's Disease as “Brain‐First” Versus “Body‐First” Subtypes	28
Parkinson's Disease Is Associated with Impaired Gut–Blood Barrier for Short‐Chain Fatty Acids	28
How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?	28
Functional Connectomics and Disease Progression in Drug‐Naïve Parkinson's Disease Patients	28
Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12‐Week, Randomized, Controlled Study	28
Age at Onset of LRRK2 p.Gly2019Ser Is Related to Environmental and Lifestyle Factors	28
Resting‐State Functional Connectivity Predicts STN DBS Clinical Response	28
Air Pollution and the Risk of Parkinson's Disease: A Review	27
Apathy Induced by Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A Meta‐Analysis	27
Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment	27
Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease	27
Dynamics of Top‐Down Control and Motor Networks in Parkinson's Disease	27

Striatal Blood–Brain Barrier Opening in Parkinson's Disease Dementia: A Pilot Exploratory Study	27
Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease	27
Allogeneic Bone Marrow–Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease	27
Treatment of *CSF1R*‐Related Leukoencephalopathy: Breaking New Ground	26
Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson's Disease?	26
Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial	26
CD4+ T‐cell Transcription Factors in Idiopathic REM Sleep Behavior Disorder and Parkinson's Disease	26
Laryngeal Movement Disorders in Multiple System Atrophy: A Diagnostic Biomarker?	26
Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study	26
Brain Motor Network Changes in Parkinson's Disease: Evidence from Meta‐Analytic Modeling	26
Locus Coeruleus Integrity from 7 T MRI Relates to Apathy and Cognition in Parkinsonian Disorders	25
High Glucosylceramides and Low Anandamide Contribute to Sensory Loss and Pain in Parkinson's Disease	25
A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease	25
GDNF/RET Signaling Pathway Activation Eliminates Lewy Body Pathology in Midbrain Dopamine Neurons	25
Is Levodopa Response a Valid Indicator of Parkinson's Disease?	25
Linking Parkinson's Disease and Melanoma: Interplay Between α‐Synuclein and Pmel17 Amyloid Formation	25
Timed Up and Go Test and the Risk of Parkinson's Disease: A Nation‐wide Retrospective Cohort Study	25
Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment	25
Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy	25
Dysregulated Brain Cholesterol Metabolism Is Linked to Neuroinflammation in Huntington's Disease	25
Magnetic Susceptibility Associates With Dopaminergic Deficits and Cognition in Parkinson's Disease	25
Highlighting the Dystonic Phenotype Related to GNAO1	25
Inflammation in Experimental Models of α‐Synucleinopathies	24
Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline	24
Olfactory Dysfunction in Recovered Coronavirus Disease 2019 (COVID‐19) Patients	24
Longitudinal Changes in Parkinson's Disease Symptoms with and Without Rapid Eye Movement Sleep Behavior Disorder: The Oxford Discovery Cohort Study	24
Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease	24
Cognitive Behavioral Therapy for Anxiety in Parkinsonʼs Disease: A Randomized Controlled Trial	24
RFC1 Intronic Repeat Expansions Absent in Pathologically Confirmed Multiple Systems Atrophy	24
Real‐Life Turning Movements Capture Subtle Longitudinal and Preataxic Changes in Cerebellar Ataxia	24
α‐Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives	24
Juvenile‐Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review	24
Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations	24
Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF‐α Pathway	24
Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of Leucine‐Rich Repeat Kinase 2 G2019S Carriers: A Novel Enzyme‐Linked Immunosorbent Assay–Base	24
An Update on the Phenotype, Genotype and Neurobiology of ADCY5‐Related Disease	24
Spinal Cord Stimulation for Very Advanced Parkinson's Disease: A 1‐Year Prospective Trial	24
Once‐Weekly Subcutaneous Delivery of Polymer‐Linked Rotigotine (SER‐214) Provides Continuous Plasma Levels in Parkinson's Disease Patients	24
Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression	24
Gaps, Controversies, and Proposed Roadmap for Research in Normal Pressure Hydrocephalus	24
Concomitant Medication Usage with Levodopa‐Carbidopa Intestinal Gel: Results from the COSMOS Study	24
Consensus Guidelines on Rodent Models of Restless Legs Syndrome	23
In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3	23
Functional Topography of the Human Subthalamic Nucleus: Relevance for Subthalamotomy in Parkinson's Disease	23
Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease	23
Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK‐PD Study)	23
Echo‐Focusing in Transcranial Focused Ultrasound Thalamotomy for Essential Tremor: A Feasibility Study	23
Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders	23
Clinical and Imaging Progression in the PARS Cohort: Long‐Term Follow‐up	23
Dopamine D1 Receptors Regulate Spines in Striatal Direct‐Pathway and Indirect‐Pathway Neurons	23
Telemedicine in Movement Disorders: Leçons du COVID‐19	23
Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity	23
Implementation of a Novel Bluetooth Technology for Remote Deep Brain Stimulation Programming: The Pre– and Post–COVID‐19 Beijing Experience	23
A Chlorzoxazone‐Baclofen Combination Improves Cerebellar Impairment in Spinocerebellar Ataxia Type 1	23
Movement Disorders in the World of COVID‐19	23
Neuroticism and Risk of Parkinson's Disease: A Meta‐Analysis	22
DNAJC6 Mutations Disrupt Dopamine Homeostasis in Juvenile Parkinsonism‐Dystonia	22
Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population	22
Online Mapping With the Deep Brain Stimulation Lead: A Novel Targeting Tool in Parkinson's Disease	22
Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease	22
Clinical Conditions “Suggestive of Progressive Supranuclear Palsy”—Diagnostic Performance	22
The Pathophysiological Correlates of Parkinson's Disease Clinical Subtypes	22
A Novel DBS Paradigm for Axial Features in Parkinson's Disease: A Randomized Crossover Study	22
White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease	22
Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease	22
Expanding Data Collection for the MDSGene Database: X‐linked Dystonia‐Parkinsonism as Use Case Example	22
Accurate Detection of α‐Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa	22
A Post‐COVID‐19 Parkinsonism in the Future?	22
FDG‐PET Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal Syndrome	22
A Randomized, Placebo‐Controlled Crossover Study with Dipyridamole for Restless Legs Syndrome	22
A Gain‐of‐Function Mutation in KCNMA1 Causes Dystonia Spells Controlled With Stimulant Therapy	22
Profiling the Biochemical Signature of GBA‐Related Parkinson's Disease in Peripheral Blood Mononuclear Cells	22
Levodopa‐Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism	21
Disruption of Brainstem Structural Connectivity in REM Sleep Behavior Disorder Using 7 Tesla Magnetic Resonance Imaging	21
A Double‐Blind, Randomized, Controlled Trial of Lovastatin in Early‐Stage Parkinson's Disease	21
The Emerging Role of Phosphodiesterases in Movement Disorders	21
Cerebrospinal α‐Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort	21
Abstract	21
Idiopathic Non‐task‐Specific Upper Limb Dystonia, a Neglected Form of Dystonia	21
Mutation Analysis of DNAJC Family for Early‐Onset Parkinson's Disease in a Chinese Cohort	21
Dietary Antioxidants and Risk of Parkinson's Disease in the Singapore Chinese Health Study	21
Striatal Dopamine Deficit and Motor Impairment in Idiopathic Normal Pressure Hydrocephalus	21
Motor Onset Topography and Progression in Parkinson's Disease: the Upper Limb Is First	21
Polyglutamine‐Expanded Ataxin‐3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood	21
Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression	21
Genotype–Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review	21
Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent‐Wide Survey	21
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity	21
Paving the Way Toward Meaningful Trials in Ataxias: An Ataxia Global Initiative Perspective	21
Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease	21
Perampanel Inhibits α‐Synuclein Transmission in Parkinson's Disease Models	21
Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans	20
A New Stimulation Mode for Deep Brain Stimulation in Parkinson's Disease: Theta Burst Stimulation	20
Is Persistent Motor or Vocal Tic Disorder a Milder Form of Tourette Syndrome?	20
Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease	20